Shan Shouqin, Hui Guangyan, Hou Fanggao, Shi Hua, Zhou Guoqing, Yan Han, Wang Lu, Liu Jinfeng
Qingdao First Sanatorium of Jinan Military Region, Qingdao, 266071, Shandong, People's Republic of China.
Qingdao Second Sanatorium of Jinan Military Region, Qingdao, 266071, Shandong, People's Republic of China.
Neurol Sci. 2015 Oct;36(10):1799-804. doi: 10.1007/s10072-015-2252-8. Epub 2015 May 23.
Glioma represents a disparate group of tumors characterized by high invasion ability, and therefore it is of clinical significance to identify molecular markers and therapeutic targets for better clinical management. Previously, metastasis-associated protein family (MTA) is considered to promote tumor cell invasion and metastasis of human malignancies. Recently, the newly identified MTA3 has been shown to play conflicting roles in human malignancies, while the expression pattern and potential clinical significance of MTA3 in human glioma have not been addressed yet. In the present study, we investigated the protein expression of MTA3 by immunohistochemistry assay and analyzed its association with glioma prognosis in 186 cases of patients. Results showed that MTA3 expression was decreased in glioma compared with that in normal brain (P < 0.05). In addition, tumors with high MTA3 expression were more likely to be of low WHO grade (P = 0.005) and reserve of body function (P = 0.014). Survival analysis showed that decreased MTA3 expression was independently associated with unfavorable overall survival of patients (P < 0.001). These results provide the first evidence that MTA3 expression was decreased in human glioma and negatively associated with prognosis of patients, suggesting that MTA3 may play a tumor suppressor role in glioma.
神经胶质瘤是一组具有高侵袭能力的不同类型肿瘤，因此识别分子标志物和治疗靶点以改善临床管理具有重要临床意义。此前，转移相关蛋白家族（MTA）被认为可促进人类恶性肿瘤的肿瘤细胞侵袭和转移。最近，新发现的MTA3在人类恶性肿瘤中表现出相互矛盾的作用，而MTA3在人类神经胶质瘤中的表达模式和潜在临床意义尚未得到研究。在本研究中，我们通过免疫组织化学分析研究了186例患者中MTA3的蛋白表达，并分析了其与神经胶质瘤预后的关系。结果显示，与正常脑组织相比，神经胶质瘤中MTA3表达降低（P < 0.05）。此外，MTA3高表达的肿瘤更可能为WHO低级别（P = 0.005）且身体功能储备较好（P = 0.014）。生存分析表明，MTA3表达降低与患者总体生存不良独立相关（P < 0.001）。这些结果首次证明，MTA3在人类神经胶质瘤中表达降低，且与患者预后呈负相关，提示MTA3可能在神经胶质瘤中发挥肿瘤抑制作用。
